• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Intern Med . Study on Continuation of Antibody Prevalence Six Months after Detection of Subclinical Severe Acute Respiratory Syndrome Coronavirus 2

tetano

Editor, Senior Moderator
Intern Med


. 2021 Nov 6.
doi: 10.2169/internalmedicine.8019-21. Online ahead of print.
Study on Continuation of Antibody Prevalence Six Months after Detection of Subclinical Severe Acute Respiratory Syndrome Coronavirus 2 Infections


Ikuro Matsuba[SUP] 1 [/SUP], Tetsuo Takuma[SUP] 1 [/SUP], Nobuo Hatori[SUP] 1 [/SUP], Masahiko Takai[SUP] 1 [/SUP], Yoshiyuki Watanabe[SUP] 1 [/SUP], Nobukazu Takada[SUP] 1 [/SUP], Satoru Kishi[SUP] 1 [/SUP], Yoko Matsuzawa[SUP] 1 [/SUP], Tetsuo Nishikawa[SUP] 1 [/SUP], Tomoyuki Kunishima[SUP] 1 [/SUP], Hisakazu Degawa[SUP] 1 [/SUP], Masanori Nishikawa[SUP] 1 [/SUP], Yoshiaki Ono[SUP] 1 [/SUP], Akira Kanamori[SUP] 1 [/SUP]



Affiliations

Abstract

Objective To examine the continuation of antibody prevalence and background factors in antibody-positive subjects after asymptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Methods A study was carried out to investigate the SARS-CoV-2 antibody (IgG) prevalence. SARS-CoV-2 antibodies (IgG) were measured and analyzed with immunochromatographic tests. Patients Among 1603 subjects, comprising patients, physicians, and nurses at 65 medical institutes in Kanagawa, Japan, 39 antibody-positive subjects received follow-up for 6 months. Results Of the 33 subjects who consented to the follow-up (23 patients and 10 medical professionals), continued positivity of IgG antibodies was confirmed in 11 of 32 cases (34.4%) after 2 months, 8 of 33 (24.2%) after 4 months, and 8 of 33 (24.2%) after 6 months. A significant difference was found in the sleeping time, drinking habits, hypertension, and use of angiotensin-receptor blockers on comparing subject background characteristics among three groups: patients with antibody production that continued for six months after the first detection of positivity, patients in whom antibody production stopped at four months, and patients in whom antibody production stopped at two months. Conclusions The continuation rate of IgG antibody prevalence was 24.2% at 6 months after the first detection of antibody positivity in cases with asymptomatic coronavirus disease 2019 (COVID-19) infections. This percentage is low compared with the antibody continuation rate in patients who have recovered from symptomatic COVID-19 infection.

Keywords: COVID-19; SARS-CoV-2 IgG antibody; epidemiological survey; immunochromatography; subclinical infection.
 
Back
Top Bottom